ProCE Banner Activity

SOHO-01: Phase I/II Study of BAY 2927088 for Previously Treated HER2-Mutant NSCLC

Conference Coverage
Slideset

In the SOHO-01 study, the HER2 tyrosine kinase inhibitor BAY 2927088 demonstrated manageable safety and antitumor activity in patients with NSCLC and HER2-activating mutations previously treated with a HER2 antibody–drug conjugate or without a previous HER2-targeted therapy.

Released: April 09, 2025

Expiration: October 08, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc